SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

Luis D’Marco, María Jesús Puchades, Miguel Ángel Serra, Lorena Gandía, Sergio Romero-Alcaide, Elena Giménez-Civera, Pablo Molina, Nayara Panizo, Javier Reque and José Luis Gorriz
Additional contact information
Luis D’Marco: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
María Jesús Puchades: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
Miguel Ángel Serra: School of Medicine, Universidad de Valencia, 46010 Valencia, Spain
Lorena Gandía: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
Sergio Romero-Alcaide: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
Elena Giménez-Civera: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
Pablo Molina: School of Medicine, Universidad de Valencia, 46010 Valencia, Spain
Nayara Panizo: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain
Javier Reque: Nephrology Department, Hospital de Castellón, 12004 Castellón, Spain
José Luis Gorriz: Nephrology Department, Hospital Clínico Universitario (INCLIVA), 46010 Valencia, Spain

IJERPH, 2021, vol. 18, issue 11, 1-6

Abstract: Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with vaccination in the case of HBV and effective viral infection treatment for HCV. In this sense, a universal SARS-CoV-2 screening and contact precaution appear to be effective in preventing further transmission. Finally, regarding the progress, an international consensus with updated protocols that prioritize between old and new indicators would seem a reasonable tool to address these unexpended changes for the nephrology community.

Keywords: chronic kidney disease; hepatitis; SARS-CoV-2; COVID19; dialysis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/11/5748/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/11/5748/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:11:p:5748-:d:563349

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().